Aspen Pharmacare Holdings Limited

DB:LDZA Stock Report

Market Cap: €3.9b

Aspen Pharmacare Holdings Valuation

Is LDZA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LDZA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Discounted Cash Flow
Simply Wall St
€13.52
Fair Value
34.5% undervalued intrinsic discount
4
Number of Analysts

Below Fair Value: LDZA (€8.85) is trading below our estimate of fair value (€13.52)

Significantly Below Fair Value: LDZA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LDZA?

Key metric: As LDZA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LDZA. This is calculated by dividing LDZA's market cap by their current earnings.
What is LDZA's PE Ratio?
PE Ratio17x
EarningsR4.40b
Market CapR74.78b

Price to Earnings Ratio vs Peers

How does LDZA's PE Ratio compare to its peers?

The above table shows the PE ratio for LDZA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average22x
DMP Dermapharm Holding
23.2x17.3%€2.1b
MRK Merck KGaA
22.6x10.2%€60.9b
PSG PharmaSGP Holding
17.9x14.1%€335.7m
1SXP SCHOTT Pharma KGaA
24.2x13.9%€3.6b
LDZA Aspen Pharmacare Holdings
17x21.7%€74.8b

Price-To-Earnings vs Peers: LDZA is good value based on its Price-To-Earnings Ratio (17x) compared to the peer average (22x).

Price to Earnings Ratio vs Industry

How does LDZA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
LDZA 17.0xIndustry Avg. 22.1xNo. of Companies9PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LDZA is good value based on its Price-To-Earnings Ratio (17x) compared to the European Pharmaceuticals industry average (22.4x).

Price to Earnings Ratio vs Fair Ratio

What is LDZA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LDZA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio17x
Fair PE Ratio19x

Price-To-Earnings vs Fair Ratio: LDZA is good value based on its Price-To-Earnings Ratio (17x) compared to the estimated Fair Price-To-Earnings Ratio (19x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LDZA forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€8.85
€11.30
+27.6%
8.2%€12.43€9.93n/a4
Feb ’26€9.30
€11.30
+21.5%
8.9%€12.30€9.82n/a4
Jan ’26€8.65
€11.81
+36.5%
7.0%€12.69€10.71n/a4
Dec ’25€8.65
€11.84
+36.9%
6.6%€12.43€10.50n/a4
Nov ’25€9.20
€12.19
+32.5%
1.4%€12.41€11.94n/a4
Oct ’25€10.10
€12.07
+19.5%
3.3%€12.70€11.64n/a4
Sep ’25€12.00
€12.45
+3.7%
6.2%€13.60€11.67n/a4
Aug ’25€12.60
€12.28
-2.6%
5.7%€13.50€11.59n/a5
Jul ’25€11.80
€12.28
+4.0%
5.7%€13.50€11.59n/a5
Jun ’25€11.20
€12.28
+9.6%
5.7%€13.50€11.59n/a5
May ’25€10.90
€11.49
+5.4%
3.1%€12.16€11.18n/a5
Apr ’25€10.50
€11.16
+6.3%
5.9%€12.21€10.30n/a5
Mar ’25€9.25
€10.50
+13.5%
4.9%€11.15€9.60n/a5
Feb ’25€9.35
€10.11
+8.2%
7.0%€11.18€9.26€9.305
Jan ’25€9.60
€10.18
+6.1%
6.6%€11.47€9.51€8.655
Dec ’24€8.85
€10.18
+15.1%
6.6%€11.47€9.51€8.655
Nov ’24€8.75
€10.18
+16.4%
6.6%€11.47€9.51€9.205
Oct ’24€8.55
€10.18
+19.1%
6.6%€11.47€9.51€10.105
Sep ’24€8.25
€10.29
+24.7%
9.4%€11.44€8.84€12.005
Aug ’24€9.55
€10.67
+11.8%
9.1%€11.92€9.21€12.605
Jul ’24€8.70
€10.67
+22.7%
9.1%€11.92€9.21€11.805
Jun ’24€7.95
€10.67
+34.2%
9.1%€11.92€9.21€11.205
May ’24€8.75
€10.67
+22.0%
9.1%€11.92€9.21€10.905
Apr ’24€9.35
€10.67
+14.1%
9.1%€11.92€9.21€10.505
Mar ’24€7.20
€9.75
+35.5%
12.8%€12.02€8.37€9.256
Feb ’24€7.85
€9.75
+24.2%
12.8%€12.02€8.37€9.356
Analyst Price Target
Consensus Narrative from 4 Analysts
€11.37
Fair Value
22.2% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 13:33
End of Day Share Price 2025/02/07 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andre BekkerArqaam Capital Research Offshore S.A.L.
Boitshepo SeruweAvior Capital Markets
Simon MatherBarclays